Search results for "Combination"

showing 10 items of 1379 documents

Efficacy and safety of combined diclofenac 0.1 % and gentamicin 0.3 eyedrops after phacoemulsification

1997

To study the efficacy of combined diclofenac 0.1% and gentamicin 0.3% (Digen) eyedrops to treat postoperative inflammation and prevent ocular infection in eyes having phacoemulsification.Department of Ophthalmology, University of Milan, San Paolo Hospital, Milan; Eye Clinic, University of Verona; and Department of Ophthalmology, University of Palermo, Italy.This double-masked, randomized, clinical trial comprised 90 patients; 45 received Digen and 45, gentamicin 0.3% eyedrops. The main outcome measure of the study was the reduction in signs and symptoms of inflammation, graded on a four-point scale. Also assessed were the presence of bacteria in the conjunctival swab and the proportion of p…

MaleDiclofenacAdministration Topicalmedicine.medical_treatmentEye diseaseEye Infections BacterialDiclofenacDouble-Blind MethodmedicineHumansAgedRetrospective StudiesAntibacterial agentAged 80 and overEndophthalmitisPhacoemulsificationbusiness.industryAnti-Inflammatory Agents Non-SteroidalAminoglycosideEye dropPhacoemulsificationMiddle Agedmedicine.diseaseSensory SystemsAnti-Bacterial AgentsClinical trialOphthalmologyTreatment OutcomeAnesthesiaDrug Therapy CombinationFemaleSurgeryGentamicinGentamicinsOphthalmic SolutionsSafetybusinessmedicine.drugJournal of Cataract and Refractive Surgery
researchProduct

Search for Stroke-Protecting Agents in Endothelin-1-Induced Ischemic Stroke Model in Rats

2012

Background and Objective. Ischemic stroke may initiate a reperfusion injury leading to brain damage cascades where inflammatory mechanisms play a major role. Therefore, the necessity for the novel stroke-protecting agents whose the mechanism of action is focused on their anti-inflammatory potency is still on the agenda for drug designers. Our previous studies demonstrated that cerebrocrast (a 1,4-dihydropyridine derivative) and mildronate (a representative of the aza-butyrobetaine class) possessed considerable anti-inflammatory and neuroprotective properties in different in vitro and in vivo model systems. The present study investigated their stroke-protecting ability in an endothelin-1 (ET…

MaleDihydropyridinesDrug Evaluation PreclinicalInfarctionBrain damagePharmacologyNeuroprotectionIn vivomedicineAnimalsRats WistarStrokeEndothelin-1business.industryGeneral Medicinemedicine.diseaseRatsStrokeDisease Models AnimalNeuroprotective AgentsMechanism of actionendothelin-1; ischemic stroke; neurodegeneration; protection; cerebrocrast; mildronateDrug Therapy Combinationmedicine.symptombusinessReperfusion injuryEx vivoMethylhydrazinesMedicina; Volume 48; Issue 10; Pages: 77
researchProduct

Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.

2015

Introduction Diuretic responsiveness in patients with chronic heart failure (CHF) is better assessed by urine production per unit diuretic dose than by the absolute urine output or diuretic dose. Diuretic resistance arises over time when the plateau rate of sodium and water excretion is reached prior to optimal fluid elimination and may be overcome when hypertonic saline solution (HSS) is added to high doses of furosemide. Methods Forty-two consecutively hospitalized patients with refractory CHF were randomized in a 1:1:1 ratio to furosemide doses (125 mg, 250 mg, 500 mg) so that all patients received intravenous furosemide diluted in 150 ml of normal saline (0.9%) in the first step (0–24 h…

MaleDose–response curves; Furosemide; Heart failure; Hypertonic saline; Refractory chronic heart failure; Pharmacology (medical); Medicine (all)medicine.medical_treatmentSodiumchemistry.chemical_elementHypertonic salineRefractoryDrug toleranceFurosemidemedicineRefractory chronic heart failureHumansPharmacology (medical)DiureticsAgedOriginal ResearchMedicine(all)Aged 80 and overHeart FailureSaline Solution HypertonicDose-Response Relationship Drugbusiness.industryMedicine (all)Osmolar ConcentrationSodiumFurosemideGeneral MedicineDrug ToleranceMiddle Agedmedicine.diseaseHypertonic salineDose–response relationshipchemistryHeart failureAnesthesiaChronic DiseaseDrug Therapy CombinationFemaleDiureticDose–response curvebusinessDose–response curvesmedicine.drugAdvances in therapy
researchProduct

The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey

2008

AbstractThis study related clinical effects to daily doses and serum concentrations of ziprasidone by retrospective analysis of data from a therapeutic drug monitoring (TDM) survey established for patients treated with the new antipsychotic drug. In the total sample of 463 patients ziprasidone doses ranged between 20 and 320 mg/d and correlated significantly (r2 = 0.093, P < 0.01) with serum concentrations. The latter were highly variable within and between individual patients (between patients median 67 ng/ml, 25–75th percentile 40–103 ng/ml). Pharmacokinetic interactions with comedication played a minor role. According to the clinical global impressions (CGI) scale most of the 348 pati…

MaleDrugmedicine.drug_classmedia_common.quotation_subjectAtypical antipsychotic030204 cardiovascular system & hematologyPharmacologySeverity of Illness Index030226 pharmacology & pharmacyDrug Administration SchedulePiperazines03 medical and health sciences0302 clinical medicinePharmacotherapyPharmacokineticsHumansMedicineZiprasidoneRetrospective Studiesmedia_commonDose-Response Relationship Drugmedicine.diagnostic_testMood Disordersbusiness.industryDrug interactionThiazolesPsychiatry and Mental healthTreatment OutcomePsychotic DisordersTherapeutic drug monitoringAnesthesiaPharmacodynamicsDrug Therapy CombinationFemaleDrug MonitoringbusinessAntipsychotic Agentsmedicine.drugEuropean Psychiatry
researchProduct

Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly

2011

Abstract Background Proton pump inhibitors (PPI) are among the most commonly prescribed medicines and their overuse is widespread in both primary and secondary care. Inappropriate prescription is of particular concern among elderly patients, who have often multiple comorbidities and need many drugs. Methods We evaluate the appropriateness of drugs for peptic ulcer or gastro-esophageal reflux disease (GERD) in a sample of elderly patients (65 years old or older) at admission and discharge in 38 internal medicine wards between January 2008 and December 2008, according to the presence of specific conditions or gastro-toxic drug combinations. Results Among 1155 patients eligible for the analysi…

MaleDrugmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectInappropriate PrescribingDiseaseappropriatenesselderly patientselderlyGastroenterologyCohort StudiesPharmacotherapyInternal medicineappropriateness; elderly; elderly patients; inappropriate prescription; proton pump inhibitorsPrevalenceInternal MedicinemedicineHumansMedical prescriptionpeptic ulcerAgedmedia_commonAged 80 and overSettore MED/12 - GastroenterologiaEvidence-Based Medicinebusiness.industrymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E Pediatrichedigestive system diseasesdrug therapy)inappropriate prescriptionConcomitantCohortGastroesophageal Refluxpeptic ulcer; drug therapy); Prevalence; hospitalization; elderlyGERDDrug Therapy CombinationFemaleGuideline Adherenceproton pump inhibitorsbusinessProton pump inhibitors Appropriateness ElderlyhospitalizationCohort studyEuropean Journal of Internal Medicine
researchProduct

Effects of co-administration of bupropion and nicotinic agonists on the elevated plus-maze test in mice

2005

There is evidence that the cholinergic nicotinic system is involved in the modulation of anxiety. Anxiolytic and anxiogenic effects of nicotine agonists have been reported in mice. Bupropion is an antidepressant drug which may alleviate some symptoms of nicotine withdrawal, although its effects on anxiety are not clear. It has been suggested that the interaction between bupropion and nicotinic mechanisms could be complex. The aim of the present study was to investigate acute effects of co-administration of bupropion and nicotinic agonists on the elevated plus-maze test in NMRI mice. Effects of nicotine, lobeline, and cytisine (0.35 and 0.175 mg/kg), administered alone or combined with bupro…

MaleElevated plus mazemedicine.drug_classPharmacologyAnxiolyticNicotineMicechemistry.chemical_compoundDopamine Uptake Inhibitorsmental disordersmedicineAnimalsLobelineNicotinic AgonistsMaze LearningBupropionBiological PsychiatryPharmacologyBupropionAnalysis of VarianceBehavior AnimalDose-Response Relationship Drugbusiness.industrymedicine.diseaseDrug CombinationsNicotinic agonistNicotine withdrawalchemistryAnxiogenicbusinesspsychological phenomena and processesmedicine.drugProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.

2008

We investigated the effect of atorvastatin monotherapy and combined treatment with atorvastatin and pioglitazone on intima-media thickness, vascular function and the cardiovascular risk profile. In all, 148 patients (76 male, 72 female; aged 61.4±6.5 years; body mass index [BMI] 29.2±4.1 kg/m2; mean±SD) with increased cardiovascular (CV) risk factors were randomised. Intima-media thickness (IMT), the augmentation index (Aix@75), the microvascular response to acetylcholine (LDF), lipid status, and plasma levels of intact proinsulin, adiponectin, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), sCD40L, P-selectin, tissue plasminogen activator …

MaleEndocrinology Diabetes and MetabolismAtorvastatinBlood lipidsBlood Pressurechemistry.chemical_compoundGermanyAtorvastatinMedicineProspective StudiesSkinUltrasonographyeducation.field_of_studymedicine.diagnostic_testMiddle AgedLipidsTreatment OutcomeCardiovascular DiseasesRadial ArteryDrug Therapy CombinationFemaleInflammation MediatorsCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyCarotid Artery CommonPopulationRisk AssessmentDouble-Blind MethodInternal medicineInternal MedicineHumansPyrroleseducationAgedAdiponectinPioglitazonebusiness.industryCholesterolMicrocirculationAtherosclerosisEndocrinologychemistryHeptanoic AcidsThiazolidinedionesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLipid profilePioglitazoneLipoproteinDiabetesvascular disease research
researchProduct

Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildro…

2004

Mildronate [3-(2,2,2-trimethylhydrazine) propionate (THP)] is an antiischemic drug acting mainly via inhibition of fatty acid beta-oxidation. Some effects of the drug cannot be explained by the latter mechanism. We tested the eventual nitric oxide (NO) dependence of the mildronate action. Mildronate, gamma-butyrobetaine (GBB) and GBB methyl ester induced transient increases in nitric oxide (NO) concentrations in rat blood and myocardium. In vitro, these compounds neither modified the activities of purified neuronal and endothelial recombinant nitric oxide synthases (NOSs) nor were able to interact with their active site. GBB induced vasodilatation at high concentrations only (EC50 = 5 x 10(…

MaleEndotheliumNitric Oxide Synthase Type IIIStereochemistryDrug Evaluation PreclinicalMyocardial IschemiaVasodilationAorta ThoracicNitric OxideMuscle Smooth VascularNitric oxidechemistry.chemical_compoundCarnitinemedicineAnimalsEndotheliumRats WistarPharmacologychemistry.chemical_classificationbiologyElectron Spin Resonance SpectroscopyActive siteFatty acidDrug SynergismRatsNitric oxide synthaseBetaineVasodilationDrug Combinationsmedicine.anatomical_structureEnzymeNG-Nitroarginine Methyl Esterchemistrybiology.proteinPropionateNitric Oxide SynthaseDitiocarbMethylhydrazinesEuropean journal of pharmacology
researchProduct

Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by antiviral treatment

2006

The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e5…

MaleEpitope-specific response; HCV/E2 glycoprotein; Human monoclonal antibodies; Therapeutic responseTime FactorsSettore MED/42 - Igiene Generale e ApplicataMolecular ConformationHepacivirusmedicine.disease_causeEpitopePolyethylene GlycolsEpitopeschemistry.chemical_compoundViral Envelope ProteinsAntibody SpecificityHCV/E2 glycoproteinNeutralizing antibodyInfectivitybiologyViral Core ProteinsMiddle AgedHepatitis CEpitope-specific responseTreatment OutcomeInfectious DiseasesDisease ProgressionDrug Therapy CombinationFemaleAntibodyAdultmedicine.drug_classHepatitis C virusMonoclonal antibodyAntiviral AgentsVirusNeutralization TestsVirologyRibavirinmedicineHumansViremiaRibavirintherapeutic responseInterferon-alphaHepatitis C AntibodiesVirologyHuman monoclonal antibodieschemistryImmunologybiology.proteinhuman monoclonal antibodietope-specific response5' Untranslated Regions
researchProduct

Long-term efficacy of botulinum toxin A for treatment of blepharospasm,hemifacial spasm, and spastic entropion: a multicentre study using two drug-do…

2009

PURPOSE: To investigate the long-term effectiveness and safety of botulinum neurotoxin A (BoNT-A) treatment in patients with blepharospasm (BEB), hemifacial spasm (HFS), and entropion (EN) and to use for the first time two modified indexes, 'botulin toxin escalation index-U' (BEI-U) and 'botulin toxin escalation index percentage' (BEI-%), in the dose-escalation evaluation. METHODS: All patients in this multicentre study were followed for at least 10 years and main outcomes were clinical efficacy, duration of relief, BEI-U and BEI-%, and frequency of adverse events. RESULTS: BEB, HFS, and EN patients received a mean BoNT-A dose with a significant inter-group difference (P<0.0005, respectivel…

MaleEye diseaseEcchymosisBlepharospasmBlepharospasmBlepharospasm Hemifacial spasmPtosismedicineHumansHemifacial SpasmLongitudinal StudiesBotulinum Toxins Type AAdverse effectAgedDiplopiaAged 80 and overDose-Response Relationship Drugbusiness.industrySettore MED/30 - Malattie Apparato VisivoEntropionMiddle Agedmedicine.diseasebotulinum toxin A; Blepharospasm Hemifacial spasm; entropion; drug-dose escalation indexdrug-dose escalation indexEntropionOphthalmologyDrug CombinationsNeuromuscular AgentsMuscle SpasticityAnesthesiaFemalemedicine.symptombotulinum toxin AbusinessHemifacial spasmFollow-Up Studies
researchProduct